Biological therapies in primary Sjögren's syndrome

Abstract

Introduction: Primary Sjögren's syndrome (PSS) is a relatively common immune-mediated condition characterized by oral and ocular dryness, fatigue, musculoskeletal pain and poor health-related quality of life. Other extra-glandular organs can also be affected and PSS is associated with a markedly increased risk of lymphoma. Furthermore, the health-economic cost for PSS is substantial. There is currently no effective treatment available. With better understanding of the pathophysiology of PSS and advances in technologies, it is now possible to develop biological therapies to target specific molecules or molecular pathways that are important in PSS pathogenesis. Indeed, a limited number of biological therapies have already been tested in PSS with mixed successes.

Areas covered: Published data on the use of biological therapies in PSS, the possible roles for other biological therapies and the potential challenges for their use.

Expert opinion: The use of biological agents targeting key cellular and molecular pathways in PSS pathogenesis represents a promising therapeutic strategy. Clinical trials assessing the efficacy of biological therapies in PSS should be encouraged but patient selection and outcome measures used in these studies must be carefully considered to ensure that the true effects of biological therapies on the outcomes of PSS are being appropriately evaluated.

Keywords::

• B-cell growth factors
• B-cells
• biological therapies
• interleukin-6
• primary Sjögren's syndrome
• type I interferons

Notes

This box summarizes key points contained in the article.